1. Home
  2. Analysis
  3. Micafungin
  4. Valcyte

Micafungin and Valcyte drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Micafungin (micafungin sodium) and Valcyte (valganciclovir hydrochloride). Common drug interactions include duodenal ulcer among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people have when they take Micafungin and Valcyte. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Micafungin?

Micafungin has active ingredients of micafungin sodium. eHealthMe is studying from 6,562 Micafungin users. Check the latest studies of Micafungin.

What is Valcyte?

Valcyte has active ingredients of valganciclovir hydrochloride. It is often used in cmv - immunocompromised host. eHealthMe is studying from 6,409 Valcyte users. Check the latest studies of Valcyte.

On Jul, 06, 2026

25 people who take Micafungin and Valcyte together, and have interactions are studied.

Micafungin and Valcyte drug interactions.

What are the common drug interactions of Micafungin and Valcyte, by gender? *:

female:

  1. Duodenal ulcer
  2. Fatigue (feeling of tiredness)
  3. Pneumonia
  4. Sinus disorder (disease of sinus)
  5. Blood potassium increased
  6. Candida sepsis (candida in blood stream)
  7. Coma (state of unconsciousness lasting more than six hours)
  8. Encephalopathy (functioning of the brain is affected by some agent or condition)
  9. Enterococcal infection
  10. Infection

male:

  1. Pyrexia (fever)
  2. Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
  3. Drug ineffective
  4. Immunosuppressant drug level increased
  5. Death
  6. Abdominal distension
  7. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  8. Alanine aminotransferase increased
  9. Blood cholesterol increased
  10. Blood glucose increased

What are the common drug interactions of Micafungin and Valcyte, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Blast cell count increased
  2. Disease progression

20-29:

  1. Cough
  2. Diarrhoea
  3. Abdominal distension
  4. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  5. Alanine aminotransferase increased
  6. Asthenia (weakness)
  7. Blood cholesterol increased
  8. Blood glucose increased
  9. Blood urea increased
  10. Catheter site related reaction

30-39:

  1. Abdominal pain
  2. Ascites (accumulation of fluid in the abdominal cavity)
  3. Blood creatinine increased
  4. Cough
  5. Cystic fibrosis (disease of the secretary glands)
  6. Dehydration (dryness resulting from the removal of water)
  7. Depressed mood
  8. Distal intestinal obstruction syndrome (blockage of the intestines by thickened stool and occurs in individuals with cystic fibrosis)
  9. Dizziness
  10. Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)

40-49:

  1. Drug ineffective
  2. Immunosuppressant drug level increased
  3. Hepatotoxicity (chemical-driven liver damage)
  4. Pyrexia (fever)

50-59:

  1. Plasma cell myeloma (cancer that begins in plasma cells)

60+:

  1. Pericardial effusion (fluid around the heart)
  2. Pulmonary hypertension (increase in blood pressure in the lung artery)
  3. Weight increased
  4. Arthritis infective (purulent invasion of a joint by an infectious agent which produces arthritis)
  5. Bacteraemia (presence of bacteria in the blood)
  6. Death
  7. Escherichia sepsis (bacterial infection by escherichia coli)
  8. Urinary tract infection
  9. Zygomycosis (an infection caused by fungus)

What are the existing conditions these people have? *

  1. Human Herpesvirus 6 Infection: 6 people, 24.00%
  2. Pulmonary Mass: 4 people, 16.00%
  3. Cytomegalovirus Infection: 4 people, 16.00%
  4. Fungaemia (fungi circulate in the blood): 4 people, 16.00%
  5. Nausea (feeling of having an urge to vomit): 3 people, 12.00%
  6. Cytomegalovirus Test Positive: 3 people, 12.00%
  7. Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 3 people, 12.00%
  8. Viral Infection: 2 people, 8.00%
  9. Dizziness: 2 people, 8.00%
  10. Anaemia (lack of blood): 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Micafungin and Valcyte?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Micafungin and Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Micafungin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Micafungin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Valcyte and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on micafungin sodium and valganciclovir hydrochloride (the active ingredients of Micafungin and Valcyte, respectively), and Micafungin and Valcyte (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.